查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
2017202

急性腎損傷治療市場：按治療方法、AKI類型、最終用戶和患者群體分類 - 全球市場預測（2026-2032年）

Acute Kidney Injury Treatment Market by Treatment Type, AKI Type, End User, Patient Demographics - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 183 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計到 2025 年，急性腎損傷治療市場價值將達到 27.4 億美元，到 2026 年將成長至 29.6 億美元，到 2032 年將達到 49.8 億美元，複合年成長率為 8.90%。

主要市場統計數據
基準年（2025 年） 27.4億美元
預計年份（2026年） 29.6億美元
預測年份（2032年） 49.8億美元
複合年成長率 (%) 8.90%

策略概述：為什麼急性腎損傷治療的優先事項需要協作臨床創新、診斷準確性和系統層級回應。

急性腎損傷（AKI）在重症監護、腎臟病學和更廣泛的醫院系統之間交匯處，構成了複雜的臨床挑戰。近年來，人們越來越關注早期發現、最佳化治療方法以及連接急診、重症監護和門診追蹤的綜合護理路徑。診斷技術的進步、體外療法的逐步改進以及對藥物安全性的日益重視，都改變了臨床決策和醫療服務提供者的工作流程。同時，人口老化和慢性併發症盛行率上升等人口結構變化，增加了腎損傷高風險患者的比例，導致醫院和專科診所面臨更大的壓力，需要採用能夠減緩疾病進展和降低長期發病率的方案。

技術創新、生物標記的進步和不斷發展的護理模式如何共同作用，改變急性腎損傷的治療途徑和結果。

重塑急性腎損傷治療格局的變革既包含技術層面，也包含系統層面。技術層面，重症監護室引入連續性腎臟替代療法，推動了儀器設備的改進，提高了患者的血流動力學耐受性，並促進了與即時監測系統的整合。同時，生物標記研究的進展使得早期風險分層和更有針對性的干涉成為可能，不再僅依賴血清肌酸酐水平。這些技術變革得益於能夠聚合生理數據的數位平台，這些平台透過預測分析識別出處於危急狀態的患者，從而促進早期臨床干預。

預計 2025 年美國關稅變化的累積影響：可能重塑急性腎損傷治療的採購、供應鏈韌性和交付。

美國預計將於2025年實施新的或調整後的關稅，將帶來一系列供應側變化，可能對急性腎損傷治療的開展產生重大影響。針對醫療設備、一次性用品或零件進口的關稅措施可能會增加透析機、過濾器和一次性耗材的採購成本，而這些耗材對於住院和門診腎臟替代療法都至關重要。這些成本壓力可能迫使採購者重新評估籌資策略，考慮其他供應商，重新談判契約，並在某些情況下推遲長期使用或更換資本密集型設備。這些調整可能會對醫院系統內的臨床排班、治療方法的提供以及資本規劃產生後續影響。

將治療方法、創傷病因、醫療保健環境和人口統計群體與明確的臨床和商業性優先事項聯繫起來的關鍵細分見解。

有效的市場區隔觀點透過將治療方法、疾病亞型、醫療機構和患者群體聯繫起來，明確了臨床需求和商業性重點。基於治療類型，市場研究從透析、藥物治療和支持性護理三個角度展開，其中透析進一步細分為連續性腎臟替代療法、間歇性血液透析和連續性低效透析。藥物治療方面考慮的因素包括抗生素、利尿劑、止痛藥物和補液藥物。支持性護理著重於飲食和液體管理。這種以治療為導向的觀點強調了治療方法特定設備的功能、耗材物流和藥物安全計畫必須與臨床路徑保持一致。

美洲、歐洲、中東和非洲以及亞太地區的部署、採購和能力建設對 AKI 護理路徑產生影響的區域觀點。

區域趨勢影響急性腎損傷治療創新技術的採納、資金籌措和規模化推廣。在美洲，醫療系統優先考慮醫院重症監護能力，但對門診和居家治療方法的興趣日益濃厚，以緩解住院患者的需求。該地區的採購趨勢和支付方協議正在推動設備互通性和降低總體擁有成本 (TCO)。歐洲、中東和非洲地區呈現多樣性，有些市場優先發展重症專科中心，而有些市場則著重於擴大臨床層面的治療能力。全部區域監管環境的多樣性促使製造商採取模組化產品策略，並提供本地化的臨床證據以支持產品推廣。在亞太地區，醫院基礎設施的快速擴張，加上慢性病負擔的加重和人口老化，使得對高度擴充性的透析解決方案的需求強勁。同時，本地生產和區域供應鏈也在影響採購決策。

關鍵的企業級洞察揭示了產品創新、診斷技術和整合服務模式如何重塑急性腎損傷治療生態系統的競爭優勢。

急性腎損傷治療領域的競爭動態反映了一個由醫療設備製造商、藥品供應商、診斷試劑開發商和服務供應商組成的生態系統。醫療設備製造商正致力於改進生物相容性材料、自動化監測功能以及支援與電子健康記錄整合的介面；而耗材供應商則專注於提高供應可靠性、無菌品質和成本效益。製藥公司則著重於藥物管理計畫、正在研發的腎臟保護劑以及能夠簡化不同病患群體給藥方式的製劑。診斷試劑開發商正在開發可操作的生物標記和就地檢驗，以縮短干預時間並實現風險分層治療方案。

為醫療保健領導者和行業相關人員提供切實可行的建議，以加強供應鏈韌性並加速診斷技術的發展，同時確保報銷途徑。

產業領導者應採取果斷行動，在推動創新的同時保障醫療服務的連續性。優先透過供應商多元化、審查關稅分類以及評估關鍵零件和耗材的近岸外包方案來增強供應鏈韌性，有助於降低貿易政策突變的風險。同時，早期療育發現通常意味著創傷較小的治療方案和更好的治療效果。臨床團隊和製造商應共同設計培訓和實施服務，以減少採用新治療方法的障礙，並確保各醫療機構對治療方案的一致性。

採用嚴謹的調查方法，結合對臨床醫師的訪談、文獻整合、監管審查和情境分析，以確保研究結果的可靠性。

本分析的調查方法結合了多種途徑，以確保其穩健性和有效性。主要研究包括對臨床醫生、採購經理和行業高管進行結構化訪談，以了解臨床模式、採購限制和推廣障礙。次要研究整合了同行評審的臨床文獻、指南、醫療設備監管申報文件和公開的政策文件，以整理證據基礎並識別臨床實踐的最新變化。資料三角測量技術用於調整資訊來源之間的差異，並檢驗所呈現的主題。

簡明扼要的結論整合了推進急性腎損傷 (AKI) 治療的關鍵策略挑戰、跨部門責任和營運重點。

總之，由於技術進步、護理模式轉變以及對供應鏈和政策風險日益成長的擔憂，急性腎損傷的治療正處於轉折點。持續性腎臟替代療法（CRRT）等治療方法與不斷發展的藥物治療和支持性護理策略之間的相互作用，需要臨床醫生、製造商和保險公司的協調應對。區域和細分領域的差異至關重要。需要根據患者的人口統計特徵和醫療環境制定個人化的解決方案，而貿易政策趨勢可能會對關鍵醫療用品的採購和供應產生重大影響。擁有強力的臨床證據、穩健的營運結構和靈活的商業策略的機構將在取得成功方面擁有最大的優勢。

目錄

第1章 引言

第2章 分析方法

  • 分析設計
  • 分析框架
  • 市場規模預測
  • 數據三角測量
  • 分析結果
  • 分析的前提條件
  • 分析的局限性

第3章執行摘要

  • 首席體驗長的觀點
  • 市場規模和成長趨勢
  • 市佔率分析（2025 年）
  • FPNV定位矩陣（2025）
  • 新的商機
  • 下一代經營模式
  • 產業藍圖

第4章 市場概覽

  • 產業生態系與價值鏈分析
  • 波特五力分析
  • PESTEL 分析
  • 市場展望
  • 市場進入（GTM）策略

第5章 市場洞察

  • 消費者分析與最終用戶觀點
  • 消費者體驗基準測試
  • 機會映射
  • 分銷通路分析
  • 價格趨勢分析
  • 監理合規和標準框架
  • ESG與永續性分析
  • 中斷和風險情景
  • 成本效益分析（ROI）和成本效益分析（CBA）

第6章：美國關稅的累積影響（2025 年）

第7章：人工智慧（AI）的累積影響（2025 年）

第8章：急性腎損傷治療市場：依治療方法

  • 透析
    • 連續性腎臟替代療法（CRRT）
    • 間歇性血液透析
    • 持續低效透析（SLED）
  • 藥物治療
    • 抗生素
    • 利尿劑
    • 止痛藥
    • 補液藥物
  • 支持性護理
    • 飲食療法
    • 體液管理

第9章：急性腎損傷治療市場：依急性腎損傷類型分類

  • 內源性急性腎損傷
  • 腎後急性腎損傷
  • 急性腎前性腎損傷

第10章：急性腎損傷治療市場：依最終用戶分類

  • 門診手術中心
  • 醫院
  • 專科診所

第11章：急性腎損傷治療市場：依患者族群分類

  • 成年患者
  • 老年患者
  • 兒童患者

第12章：急性腎損傷治療市場：依地區分類

  • 北美洲和南美洲
    • 北美洲
    • 拉丁美洲
  • 歐洲、中東和非洲
    • 歐洲
    • 中東
    • 非洲
  • 亞太地區

第13章：急性腎損傷治療市場：依組別分類

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第14章：急性腎損傷治療市場：依國家分類

  • 美國
  • 加拿大
  • 墨西哥
  • 巴西
  • 英國
  • 德國
  • 法國
  • 俄羅斯
  • 義大利
  • 西班牙
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國

第15章：美國急性腎損傷治療市場

第16章：中國急性腎損傷治療市場

第17章 競爭格局

  • 市場集中度分析（2025 年）
    • 濃度比（CR）
    • 赫芬達爾-赫希曼指數 (HHI)
  • 近期趨勢及影響分析（2025 年）
  • 產品系列分析（2025 年）
  • 基準分析（2025 年）
  • Abbott Laboratories
  • Alloksys Life Sciences BV
  • Amgen Inc.
  • Asahi Kasei Medical Co., Ltd.
  • Astellas Pharma Inc.
  • B. Braun Melsungen AG
  • Baxter International, Inc.
  • Bayer AG
  • bioMerieux SA
  • CardioRenal Systems, Inc.
Product Code: MRR-035DA3C63706

The Acute Kidney Injury Treatment Market was valued at USD 2.74 billion in 2025 and is projected to grow to USD 2.96 billion in 2026, with a CAGR of 8.90%, reaching USD 4.98 billion by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 2.74 billion
Estimated Year [2026] USD 2.96 billion
Forecast Year [2032] USD 4.98 billion
CAGR (%) 8.90%

A strategic introduction explaining why acute kidney injury treatment priorities demand coordinated clinical innovation, diagnostic precision, and systems-level responses

Acute kidney injury presents a complex clinical challenge at the intersection of critical care, nephrology, and broader hospital systems. Recent years have seen an intensification of focus on early detection, modality optimization, and integrated care pathways that connect emergency, intensive care, and outpatient follow-up. Advances in diagnostics, incremental improvements in extracorporeal therapy, and heightened attention to medication safety have altered clinical decision-making and provider workflows. At the same time, demographic shifts such as an aging population and rising prevalence of chronic comorbidities increase the proportion of patients at risk for renal insults, which in turn elevates pressure on hospitals and specialty clinics to adopt protocols that reduce progression and long-term morbidity.

This introduction frames the core dynamics driving treatment choices and organizational responses. It highlights the imperative for multidisciplinary coordination, the need for faster and more precise diagnostic signals, and the growing influence of value-based considerations on modality selection and post-discharge management. By situating clinical practice trends within health-system priorities-efficiency, patient safety, and outcome optimization-this opening underscores why clinical leaders, manufacturers, and payers must align around innovations that demonstrably reduce acute kidney injury burden while remaining attentive to cost and supply chain realities.

How technological innovations, biomarker advances, and evolving care models are jointly transforming acute kidney injury treatment pathways and outcomes

Shifts reshaping acute kidney injury care are both technological and systemic. On the technological front, the adoption of continuous renal replacement therapies in intensive care settings has been accompanied by device-level refinements that improve hemodynamic tolerance and facilitate integration with real-time monitoring systems. Parallel advances in biomarker research are enabling earlier risk stratification and more targeted intervention, reducing reliance on serum creatinine alone. These technical changes are reinforced by digital platforms that aggregate physiologic data, enabling predictive analytics to identify patients at imminent risk and prompting earlier clinical responses.

Systemically, care delivery models are moving toward decentralization and greater use of ambulatory and specialty clinic settings for follow-up and supportive management. This trend reduces inpatient burden while necessitating new pathways for continuity of care, particularly for patients who transition from hospital to home with residual kidney dysfunction. Additionally, antibiotic stewardship programs, protocols to minimize exposure to nephrotoxins, and standardized fluid management pathways are becoming embedded in institutional practice, altering the incidence and severity of acute kidney injury episodes. Taken together, these shifts create opportunities for cross-disciplinary collaboration and for companies that can deliver integrated diagnostic, therapeutic, and service solutions that span the acute-to-post-acute continuum.

Projected cumulative effects from United States tariff changes in 2025 that could reshape procurement, supply chain resilience, and treatment delivery for acute kidney injury

The prospect of new or modified tariffs in the United States in 2025 introduces a set of supply-side dynamics that can materially affect acute kidney injury treatment delivery. Tariff measures focused on medical devices, disposables, or component imports can increase acquisition costs for dialysis machines, filters, and single-use consumables, which are integral to both inpatient and ambulatory renal replacement therapy. Such cost pressures may drive purchasers to reassess procurement strategies and to explore alternative suppliers, contract renegotiation, and in some cases, extended use or deferred replacement of capital-intensive equipment. These adjustments can have downstream implications for clinical scheduling, modality availability, and capital planning within hospital systems.

Beyond direct price effects, policy-driven trade changes often accelerate localization trends. Manufacturers and suppliers may respond by reconfiguring supply chains, onshoring certain capabilities, or seeking tariff classifications and exemptions for critical medical goods. Such responses can reduce long-term exposure but also create short-term disruptions as new manufacturing or distribution arrangements scale. In parallel, providers and health systems will likely intensify efforts to optimize the use of pharmacological treatments and supportive care that rely on locally sourced medications and consumables, as a hedge against imported supply volatility. Clinicians and procurement teams will need to coordinate to ensure continuity of care while navigating pricing and availability changes, and industry players that proactively communicate about supply assurance and alternative sourcing will have a competitive advantage during any tariff-driven transition.

Key segmentation insights that map treatment modalities, injury etiologies, care settings, and demographic cohorts to precise clinical and commercial priorities

An effective segmentation lens clarifies clinical needs and commercial priorities by linking treatment modalities, injury subtypes, care settings, and patient cohorts. Based on treatment type, the market is studied across dialysis, pharmacological treatment, and supportive care where dialysis is further analyzed across continuous renal replacement therapy, intermittent hemodialysis, and sustained low-efficiency dialysis; pharmacological treatment considerations encompass antibiotics, diuretics, pain management drugs, and rehydration drugs; and supportive care focuses on dietary management and fluid management. This treatment-oriented view highlights how modality-specific device features, consumable logistics, and medication safety programs must align with the clinical pathway.

Based on AKI type, the analysis differentiates intrinsic renal acute kidney injury, post-renal acute kidney injury, and pre-renal acute kidney injury to surface diagnostic needs and targeted interventions that vary by etiology. Based on end user, the review segments ambulatory surgical centers, hospitals, and specialty clinics to show how engineering requirements, staffing models, and capital deployment differ across settings. Based on patient demographics, attention to adult patients, geriatric patients, and pediatric patients reveals nuances in dosing, device size, and follow-up intensity. Integrating these segmentation axes provides a multidimensional picture in which product design, clinical protocols, and service models must be calibrated to fit distinct combinations of modality, etiology, care setting, and patient age profile.

Regional perspectives on adoption, procurement, and capacity building across the Americas, Europe Middle East & Africa, and Asia-Pacific that influence AKI care pathways

Regional dynamics shape how acute kidney injury treatment innovations are adopted, financed, and scaled. In the Americas, health systems emphasize hospital-based critical care capacity with a growing interest in ambulatory and home-based modalities to alleviate inpatient demand; procurement trends and payer arrangements in this region incentivize device interoperability and total-cost-of-care initiatives. Europe, Middle East & Africa displays heterogeneity, where some markets prioritize centralized specialist centers and others focus on expanding point-of-care capabilities; regulatory diversity across the region drives manufacturers to pursue modular product strategies and regionally tailored clinical evidence to support adoption. In the Asia-Pacific region, rapid expansion of hospital infrastructure, combined with a rising burden of chronic diseases and aging populations, creates strong demand for scalable dialysis solutions, while local manufacturing and regional supply chains influence procurement decisions.

These regional distinctions have implications for clinical protocols, distribution partnerships, and service models. Companies and health systems must tailor engagement strategies to each region's mix of inpatient capacity, outpatient growth, regulatory environment, and sourcing realities. Cross-border learning can accelerate adoption of best practices, but regional adaptation is essential to account for differences in workforce, reimbursement, and infrastructure maturity. Consequently, regional strategic planning should prioritize flexible product portfolios, adaptive pricing models, and investments in training that accommodate local care delivery patterns.

Critical company-level insights revealing how product innovation, diagnostics, and integrated service models are reshaping competitive advantage in AKI treatment ecosystems

Competitive dynamics in acute kidney injury treatment reflect an ecosystem of device manufacturers, pharmaceutical suppliers, diagnostics developers, and service providers. Device makers are investing in improved biocompatible materials, automated monitoring functions, and interfaces that support integration with electronic health records, while suppliers of consumables focus on supply reliability, sterilization quality, and cost-efficiency. Pharmaceutical companies are concentrating on stewardship programs, nephroprotective agents in development, and formulations that simplify dosing in heterogeneous patient populations. Diagnostic developers are advancing actionable biomarkers and point-of-care assays that shorten the time to intervention and enable risk-stratified treatment pathways.

Across this landscape, strategic moves such as alliances with hospital systems, bundled service offerings, and extended warranties are common as companies seek to reduce total cost of ownership for providers. There is also notable activity in after-sales service, remote monitoring, and training programs to ensure devices deliver consistent performance in high-acuity environments. Competitive advantage increasingly depends on the ability to present an integrated value proposition that couples technology with clinical evidence, service reliability, and clear pathways for reimbursement and implementation within complex care settings.

Actionable recommendations for healthcare leaders and industry stakeholders to enhance supply chain resilience, accelerate diagnostics, and secure reimbursement pathways

Industry leaders should take decisive steps to protect continuity of care while advancing innovation. Prioritize strengthening supply chain resilience by diversifying suppliers, reviewing tariff classifications, and evaluating nearshoring options for critical components and consumables to reduce exposure to sudden trade policy shifts. Simultaneously, accelerate investments in diagnostics and predictive analytics that enable earlier intervention, as earlier detection frequently leads to less invasive treatment needs and better outcomes. Clinical teams and manufacturers should co-design training and implementation services to reduce barriers to adoption of newer modalities and to ensure consistent protocol adherence across sites.

Engage payers and health systems early to demonstrate real-world performance and to construct reimbursement pathways that reflect value over time rather than episodic cost. Invest in modular product designs and scalable service models that can be adapted across hospitals, specialty clinics, and ambulatory surgical centers to capture diversified demand. Finally, develop clear communication strategies about supply assurance and contingency planning to reassure procurement teams and clinicians during periods of policy-driven market uncertainty. These combined actions will position organizations to respond nimbly to shifting regulatory, commercial, and clinical conditions.

A rigorous methodological framework combining clinician interviews, literature synthesis, regulatory review, and scenario analysis to ensure robust insights

The research methodology underpinning this analysis combines a multi-pronged approach to ensure robustness and relevance. Primary research included structured interviews with clinicians, procurement leaders, and industry executives to capture real-world practice patterns, procurement constraints, and adoption barriers. Secondary research synthesized peer-reviewed clinical literature, guideline publications, device regulatory filings, and publicly available policy documents to map the evidence base and to identify recent shifts in practice. Data triangulation techniques were used to reconcile differences across sources and to validate emerging themes.

Analytical methods included scenario analysis to assess potential supply chain and policy outcomes, qualitative coding of interview transcripts to surface recurring operational challenges, and comparative assessments of modality features and workflows. Limitations are acknowledged: the analysis relies on available clinical studies and expert opinion, which may evolve as new trials and regulatory decisions are published. To mitigate these limitations, the research integrated diverse stakeholder perspectives and prioritized findings with multi-source corroboration to present actionable, evidence-aligned insights.

A concise conclusion synthesizing the strategic imperatives, cross-sector responsibilities, and operational priorities essential for advancing AKI care

In conclusion, acute kidney injury treatment is at an inflection point driven by technological advances, shifting care models, and heightened attention to supply chain and policy risks. The interplay between modalities such as continuous renal replacement therapy and evolving pharmacological and supportive care strategies requires coordinated responses from clinicians, manufacturers, and payers. Regional and segmentation nuances matter: different patient cohorts and care settings demand tailored solutions, and trade policy developments can materially affect procurement and availability of critical supplies. The organizations best positioned for success will be those that combine robust clinical evidence, resilient operations, and flexible commercial strategies.

Sustained progress will depend on cross-sector collaboration: clinicians adopting standardized pathways, manufacturers delivering integrated and service-oriented offerings, and health systems enabling reimbursement structures that recognize long-term value. By aligning innovation with pragmatic implementation plans and supply assurance measures, stakeholders can reduce the clinical and economic burden of acute kidney injury while improving patient outcomes across diverse care environments.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Porter's Five Forces Analysis
  • 4.4. PESTLE Analysis
  • 4.5. Market Outlook
    • 4.5.1. Near-Term Market Outlook (0-2 Years)
    • 4.5.2. Medium-Term Market Outlook (3-5 Years)
    • 4.5.3. Long-Term Market Outlook (5-10 Years)
  • 4.6. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Acute Kidney Injury Treatment Market, by Treatment Type

  • 8.1. Dialysis
    • 8.1.1. Continuous Renal Replacement Therapy (CRRT)
    • 8.1.2. Intermittent Hemodialysis
    • 8.1.3. Sustained Low-Efficiency Dialysis (SLED)
  • 8.2. Pharmacological Treatment
    • 8.2.1. Antibiotics
    • 8.2.2. Diuretics
    • 8.2.3. Pain Management Drugs
    • 8.2.4. Rehydration Drugs
  • 8.3. Supportive Care
    • 8.3.1. Dietary Management
    • 8.3.2. Fluid Management

9. Acute Kidney Injury Treatment Market, by AKI Type

  • 9.1. Intrinsic Renal Acute Kidney Injury
  • 9.2. Post-renal Acute Kidney Injury
  • 9.3. Pre-renal Acute Kidney Injury

10. Acute Kidney Injury Treatment Market, by End User

  • 10.1. Ambulatory Surgical Centers
  • 10.2. Hospitals
  • 10.3. Specialty Clinics

11. Acute Kidney Injury Treatment Market, by Patient Demographics

  • 11.1. Adult Patients
  • 11.2. Geriatric Patients
  • 11.3. Pediatric Patients

12. Acute Kidney Injury Treatment Market, by Region

  • 12.1. Americas
    • 12.1.1. North America
    • 12.1.2. Latin America
  • 12.2. Europe, Middle East & Africa
    • 12.2.1. Europe
    • 12.2.2. Middle East
    • 12.2.3. Africa
  • 12.3. Asia-Pacific

13. Acute Kidney Injury Treatment Market, by Group

  • 13.1. ASEAN
  • 13.2. GCC
  • 13.3. European Union
  • 13.4. BRICS
  • 13.5. G7
  • 13.6. NATO

14. Acute Kidney Injury Treatment Market, by Country

  • 14.1. United States
  • 14.2. Canada
  • 14.3. Mexico
  • 14.4. Brazil
  • 14.5. United Kingdom
  • 14.6. Germany
  • 14.7. France
  • 14.8. Russia
  • 14.9. Italy
  • 14.10. Spain
  • 14.11. China
  • 14.12. India
  • 14.13. Japan
  • 14.14. Australia
  • 14.15. South Korea

15. United States Acute Kidney Injury Treatment Market

16. China Acute Kidney Injury Treatment Market

17. Competitive Landscape

  • 17.1. Market Concentration Analysis, 2025
    • 17.1.1. Concentration Ratio (CR)
    • 17.1.2. Herfindahl Hirschman Index (HHI)
  • 17.2. Recent Developments & Impact Analysis, 2025
  • 17.3. Product Portfolio Analysis, 2025
  • 17.4. Benchmarking Analysis, 2025
  • 17.5. Abbott Laboratories
  • 17.6. Alloksys Life Sciences B.V.
  • 17.7. Amgen Inc.
  • 17.8. Asahi Kasei Medical Co., Ltd.
  • 17.9. Astellas Pharma Inc.
  • 17.10. B. Braun Melsungen AG
  • 17.11. Baxter International, Inc.
  • 17.12. Bayer AG
  • 17.13. bioMerieux SA
  • 17.14. CardioRenal Systems, Inc.

LIST OF FIGURES

  • FIGURE 1. GLOBAL ACUTE KIDNEY INJURY TREATMENT MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL ACUTE KIDNEY INJURY TREATMENT MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 3. GLOBAL ACUTE KIDNEY INJURY TREATMENT MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 4. GLOBAL ACUTE KIDNEY INJURY TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 5. GLOBAL ACUTE KIDNEY INJURY TREATMENT MARKET SIZE, BY AKI TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL ACUTE KIDNEY INJURY TREATMENT MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 7. GLOBAL ACUTE KIDNEY INJURY TREATMENT MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL ACUTE KIDNEY INJURY TREATMENT MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 9. GLOBAL ACUTE KIDNEY INJURY TREATMENT MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL ACUTE KIDNEY INJURY TREATMENT MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 11. UNITED STATES ACUTE KIDNEY INJURY TREATMENT MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 12. CHINA ACUTE KIDNEY INJURY TREATMENT MARKET SIZE, 2018-2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL ACUTE KIDNEY INJURY TREATMENT MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL ACUTE KIDNEY INJURY TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL ACUTE KIDNEY INJURY TREATMENT MARKET SIZE, BY DIALYSIS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL ACUTE KIDNEY INJURY TREATMENT MARKET SIZE, BY DIALYSIS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL ACUTE KIDNEY INJURY TREATMENT MARKET SIZE, BY DIALYSIS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL ACUTE KIDNEY INJURY TREATMENT MARKET SIZE, BY DIALYSIS, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL ACUTE KIDNEY INJURY TREATMENT MARKET SIZE, BY CONTINUOUS RENAL REPLACEMENT THERAPY (CRRT), BY REGION, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL ACUTE KIDNEY INJURY TREATMENT MARKET SIZE, BY CONTINUOUS RENAL REPLACEMENT THERAPY (CRRT), BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL ACUTE KIDNEY INJURY TREATMENT MARKET SIZE, BY CONTINUOUS RENAL REPLACEMENT THERAPY (CRRT), BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL ACUTE KIDNEY INJURY TREATMENT MARKET SIZE, BY INTERMITTENT HEMODIALYSIS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL ACUTE KIDNEY INJURY TREATMENT MARKET SIZE, BY INTERMITTENT HEMODIALYSIS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL ACUTE KIDNEY INJURY TREATMENT MARKET SIZE, BY INTERMITTENT HEMODIALYSIS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL ACUTE KIDNEY INJURY TREATMENT MARKET SIZE, BY SUSTAINED LOW-EFFICIENCY DIALYSIS (SLED), BY REGION, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL ACUTE KIDNEY INJURY TREATMENT MARKET SIZE, BY SUSTAINED LOW-EFFICIENCY DIALYSIS (SLED), BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL ACUTE KIDNEY INJURY TREATMENT MARKET SIZE, BY SUSTAINED LOW-EFFICIENCY DIALYSIS (SLED), BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL ACUTE KIDNEY INJURY TREATMENT MARKET SIZE, BY PHARMACOLOGICAL TREATMENT, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL ACUTE KIDNEY INJURY TREATMENT MARKET SIZE, BY PHARMACOLOGICAL TREATMENT, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL ACUTE KIDNEY INJURY TREATMENT MARKET SIZE, BY PHARMACOLOGICAL TREATMENT, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL ACUTE KIDNEY INJURY TREATMENT MARKET SIZE, BY PHARMACOLOGICAL TREATMENT, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL ACUTE KIDNEY INJURY TREATMENT MARKET SIZE, BY ANTIBIOTICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL ACUTE KIDNEY INJURY TREATMENT MARKET SIZE, BY ANTIBIOTICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL ACUTE KIDNEY INJURY TREATMENT MARKET SIZE, BY ANTIBIOTICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL ACUTE KIDNEY INJURY TREATMENT MARKET SIZE, BY DIURETICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL ACUTE KIDNEY INJURY TREATMENT MARKET SIZE, BY DIURETICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL ACUTE KIDNEY INJURY TREATMENT MARKET SIZE, BY DIURETICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL ACUTE KIDNEY INJURY TREATMENT MARKET SIZE, BY PAIN MANAGEMENT DRUGS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL ACUTE KIDNEY INJURY TREATMENT MARKET SIZE, BY PAIN MANAGEMENT DRUGS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL ACUTE KIDNEY INJURY TREATMENT MARKET SIZE, BY PAIN MANAGEMENT DRUGS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL ACUTE KIDNEY INJURY TREATMENT MARKET SIZE, BY REHYDRATION DRUGS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL ACUTE KIDNEY INJURY TREATMENT MARKET SIZE, BY REHYDRATION DRUGS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL ACUTE KIDNEY INJURY TREATMENT MARKET SIZE, BY REHYDRATION DRUGS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL ACUTE KIDNEY INJURY TREATMENT MARKET SIZE, BY SUPPORTIVE CARE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL ACUTE KIDNEY INJURY TREATMENT MARKET SIZE, BY SUPPORTIVE CARE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL ACUTE KIDNEY INJURY TREATMENT MARKET SIZE, BY SUPPORTIVE CARE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL ACUTE KIDNEY INJURY TREATMENT MARKET SIZE, BY SUPPORTIVE CARE, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL ACUTE KIDNEY INJURY TREATMENT MARKET SIZE, BY DIETARY MANAGEMENT, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL ACUTE KIDNEY INJURY TREATMENT MARKET SIZE, BY DIETARY MANAGEMENT, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL ACUTE KIDNEY INJURY TREATMENT MARKET SIZE, BY DIETARY MANAGEMENT, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL ACUTE KIDNEY INJURY TREATMENT MARKET SIZE, BY FLUID MANAGEMENT, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL ACUTE KIDNEY INJURY TREATMENT MARKET SIZE, BY FLUID MANAGEMENT, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL ACUTE KIDNEY INJURY TREATMENT MARKET SIZE, BY FLUID MANAGEMENT, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL ACUTE KIDNEY INJURY TREATMENT MARKET SIZE, BY AKI TYPE, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL ACUTE KIDNEY INJURY TREATMENT MARKET SIZE, BY INTRINSIC RENAL ACUTE KIDNEY INJURY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL ACUTE KIDNEY INJURY TREATMENT MARKET SIZE, BY INTRINSIC RENAL ACUTE KIDNEY INJURY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL ACUTE KIDNEY INJURY TREATMENT MARKET SIZE, BY INTRINSIC RENAL ACUTE KIDNEY INJURY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL ACUTE KIDNEY INJURY TREATMENT MARKET SIZE, BY POST-RENAL ACUTE KIDNEY INJURY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL ACUTE KIDNEY INJURY TREATMENT MARKET SIZE, BY POST-RENAL ACUTE KIDNEY INJURY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL ACUTE KIDNEY INJURY TREATMENT MARKET SIZE, BY POST-RENAL ACUTE KIDNEY INJURY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL ACUTE KIDNEY INJURY TREATMENT MARKET SIZE, BY PRE-RENAL ACUTE KIDNEY INJURY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 50. GLOBAL ACUTE KIDNEY INJURY TREATMENT MARKET SIZE, BY PRE-RENAL ACUTE KIDNEY INJURY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 51. GLOBAL ACUTE KIDNEY INJURY TREATMENT MARKET SIZE, BY PRE-RENAL ACUTE KIDNEY INJURY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 52. GLOBAL ACUTE KIDNEY INJURY TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 53. GLOBAL ACUTE KIDNEY INJURY TREATMENT MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 54. GLOBAL ACUTE KIDNEY INJURY TREATMENT MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 55. GLOBAL ACUTE KIDNEY INJURY TREATMENT MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 56. GLOBAL ACUTE KIDNEY INJURY TREATMENT MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 57. GLOBAL ACUTE KIDNEY INJURY TREATMENT MARKET SIZE, BY HOSPITALS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 58. GLOBAL ACUTE KIDNEY INJURY TREATMENT MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 59. GLOBAL ACUTE KIDNEY INJURY TREATMENT MARKET SIZE, BY SPECIALTY CLINICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 60. GLOBAL ACUTE KIDNEY INJURY TREATMENT MARKET SIZE, BY SPECIALTY CLINICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 61. GLOBAL ACUTE KIDNEY INJURY TREATMENT MARKET SIZE, BY SPECIALTY CLINICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 62. GLOBAL ACUTE KIDNEY INJURY TREATMENT MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2032 (USD MILLION)
  • TABLE 63. GLOBAL ACUTE KIDNEY INJURY TREATMENT MARKET SIZE, BY ADULT PATIENTS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 64. GLOBAL ACUTE KIDNEY INJURY TREATMENT MARKET SIZE, BY ADULT PATIENTS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 65. GLOBAL ACUTE KIDNEY INJURY TREATMENT MARKET SIZE, BY ADULT PATIENTS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 66. GLOBAL ACUTE KIDNEY INJURY TREATMENT MARKET SIZE, BY GERIATRIC PATIENTS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 67. GLOBAL ACUTE KIDNEY INJURY TREATMENT MARKET SIZE, BY GERIATRIC PATIENTS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 68. GLOBAL ACUTE KIDNEY INJURY TREATMENT MARKET SIZE, BY GERIATRIC PATIENTS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 69. GLOBAL ACUTE KIDNEY INJURY TREATMENT MARKET SIZE, BY PEDIATRIC PATIENTS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 70. GLOBAL ACUTE KIDNEY INJURY TREATMENT MARKET SIZE, BY PEDIATRIC PATIENTS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 71. GLOBAL ACUTE KIDNEY INJURY TREATMENT MARKET SIZE, BY PEDIATRIC PATIENTS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 72. GLOBAL ACUTE KIDNEY INJURY TREATMENT MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 73. AMERICAS ACUTE KIDNEY INJURY TREATMENT MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 74. AMERICAS ACUTE KIDNEY INJURY TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 75. AMERICAS ACUTE KIDNEY INJURY TREATMENT MARKET SIZE, BY DIALYSIS, 2018-2032 (USD MILLION)
  • TABLE 76. AMERICAS ACUTE KIDNEY INJURY TREATMENT MARKET SIZE, BY PHARMACOLOGICAL TREATMENT, 2018-2032 (USD MILLION)
  • TABLE 77. AMERICAS ACUTE KIDNEY INJURY TREATMENT MARKET SIZE, BY SUPPORTIVE CARE, 2018-2032 (USD MILLION)
  • TABLE 78. AMERICAS ACUTE KIDNEY INJURY TREATMENT MARKET SIZE, BY AKI TYPE, 2018-2032 (USD MILLION)
  • TABLE 79. AMERICAS ACUTE KIDNEY INJURY TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 80. AMERICAS ACUTE KIDNEY INJURY TREATMENT MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2032 (USD MILLION)
  • TABLE 81. NORTH AMERICA ACUTE KIDNEY INJURY TREATMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 82. NORTH AMERICA ACUTE KIDNEY INJURY TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 83. NORTH AMERICA ACUTE KIDNEY INJURY TREATMENT MARKET SIZE, BY DIALYSIS, 2018-2032 (USD MILLION)
  • TABLE 84. NORTH AMERICA ACUTE KIDNEY INJURY TREATMENT MARKET SIZE, BY PHARMACOLOGICAL TREATMENT, 2018-2032 (USD MILLION)
  • TABLE 85. NORTH AMERICA ACUTE KIDNEY INJURY TREATMENT MARKET SIZE, BY SUPPORTIVE CARE, 2018-2032 (USD MILLION)
  • TABLE 86. NORTH AMERICA ACUTE KIDNEY INJURY TREATMENT MARKET SIZE, BY AKI TYPE, 2018-2032 (USD MILLION)
  • TABLE 87. NORTH AMERICA ACUTE KIDNEY INJURY TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 88. NORTH AMERICA ACUTE KIDNEY INJURY TREATMENT MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2032 (USD MILLION)
  • TABLE 89. LATIN AMERICA ACUTE KIDNEY INJURY TREATMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 90. LATIN AMERICA ACUTE KIDNEY INJURY TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 91. LATIN AMERICA ACUTE KIDNEY INJURY TREATMENT MARKET SIZE, BY DIALYSIS, 2018-2032 (USD MILLION)
  • TABLE 92. LATIN AMERICA ACUTE KIDNEY INJURY TREATMENT MARKET SIZE, BY PHARMACOLOGICAL TREATMENT, 2018-2032 (USD MILLION)
  • TABLE 93. LATIN AMERICA ACUTE KIDNEY INJURY TREATMENT MARKET SIZE, BY SUPPORTIVE CARE, 2018-2032 (USD MILLION)
  • TABLE 94. LATIN AMERICA ACUTE KIDNEY INJURY TREATMENT MARKET SIZE, BY AKI TYPE, 2018-2032 (USD MILLION)
  • TABLE 95. LATIN AMERICA ACUTE KIDNEY INJURY TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 96. LATIN AMERICA ACUTE KIDNEY INJURY TREATMENT MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2032 (USD MILLION)
  • TABLE 97. EUROPE, MIDDLE EAST & AFRICA ACUTE KIDNEY INJURY TREATMENT MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 98. EUROPE, MIDDLE EAST & AFRICA ACUTE KIDNEY INJURY TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 99. EUROPE, MIDDLE EAST & AFRICA ACUTE KIDNEY INJURY TREATMENT MARKET SIZE, BY DIALYSIS, 2018-2032 (USD MILLION)
  • TABLE 100. EUROPE, MIDDLE EAST & AFRICA ACUTE KIDNEY INJURY TREATMENT MARKET SIZE, BY PHARMACOLOGICAL TREATMENT, 2018-2032 (USD MILLION)
  • TABLE 101. EUROPE, MIDDLE EAST & AFRICA ACUTE KIDNEY INJURY TREATMENT MARKET SIZE, BY SUPPORTIVE CARE, 2018-2032 (USD MILLION)
  • TABLE 102. EUROPE, MIDDLE EAST & AFRICA ACUTE KIDNEY INJURY TREATMENT MARKET SIZE, BY AKI TYPE, 2018-2032 (USD MILLION)
  • TABLE 103. EUROPE, MIDDLE EAST & AFRICA ACUTE KIDNEY INJURY TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 104. EUROPE, MIDDLE EAST & AFRICA ACUTE KIDNEY INJURY TREATMENT MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2032 (USD MILLION)
  • TABLE 105. EUROPE ACUTE KIDNEY INJURY TREATMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 106. EUROPE ACUTE KIDNEY INJURY TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 107. EUROPE ACUTE KIDNEY INJURY TREATMENT MARKET SIZE, BY DIALYSIS, 2018-2032 (USD MILLION)
  • TABLE 108. EUROPE ACUTE KIDNEY INJURY TREATMENT MARKET SIZE, BY PHARMACOLOGICAL TREATMENT, 2018-2032 (USD MILLION)
  • TABLE 109. EUROPE ACUTE KIDNEY INJURY TREATMENT MARKET SIZE, BY SUPPORTIVE CARE, 2018-2032 (USD MILLION)
  • TABLE 110. EUROPE ACUTE KIDNEY INJURY TREATMENT MARKET SIZE, BY AKI TYPE, 2018-2032 (USD MILLION)
  • TABLE 111. EUROPE ACUTE KIDNEY INJURY TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 112. EUROPE ACUTE KIDNEY INJURY TREATMENT MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2032 (USD MILLION)
  • TABLE 113. MIDDLE EAST ACUTE KIDNEY INJURY TREATMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 114. MIDDLE EAST ACUTE KIDNEY INJURY TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 115. MIDDLE EAST ACUTE KIDNEY INJURY TREATMENT MARKET SIZE, BY DIALYSIS, 2018-2032 (USD MILLION)
  • TABLE 116. MIDDLE EAST ACUTE KIDNEY INJURY TREATMENT MARKET SIZE, BY PHARMACOLOGICAL TREATMENT, 2018-2032 (USD MILLION)
  • TABLE 117. MIDDLE EAST ACUTE KIDNEY INJURY TREATMENT MARKET SIZE, BY SUPPORTIVE CARE, 2018-2032 (USD MILLION)
  • TABLE 118. MIDDLE EAST ACUTE KIDNEY INJURY TREATMENT MARKET SIZE, BY AKI TYPE, 2018-2032 (USD MILLION)
  • TABLE 119. MIDDLE EAST ACUTE KIDNEY INJURY TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 120. MIDDLE EAST ACUTE KIDNEY INJURY TREATMENT MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2032 (USD MILLION)
  • TABLE 121. AFRICA ACUTE KIDNEY INJURY TREATMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 122. AFRICA ACUTE KIDNEY INJURY TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 123. AFRICA ACUTE KIDNEY INJURY TREATMENT MARKET SIZE, BY DIALYSIS, 2018-2032 (USD MILLION)
  • TABLE 124. AFRICA ACUTE KIDNEY INJURY TREATMENT MARKET SIZE, BY PHARMACOLOGICAL TREATMENT, 2018-2032 (USD MILLION)
  • TABLE 125. AFRICA ACUTE KIDNEY INJURY TREATMENT MARKET SIZE, BY SUPPORTIVE CARE, 2018-2032 (USD MILLION)
  • TABLE 126. AFRICA ACUTE KIDNEY INJURY TREATMENT MARKET SIZE, BY AKI TYPE, 2018-2032 (USD MILLION)
  • TABLE 127. AFRICA ACUTE KIDNEY INJURY TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 128. AFRICA ACUTE KIDNEY INJURY TREATMENT MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2032 (USD MILLION)
  • TABLE 129. ASIA-PACIFIC ACUTE KIDNEY INJURY TREATMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 130. ASIA-PACIFIC ACUTE KIDNEY INJURY TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 131. ASIA-PACIFIC ACUTE KIDNEY INJURY TREATMENT MARKET SIZE, BY DIALYSIS, 2018-2032 (USD MILLION)
  • TABLE 132. ASIA-PACIFIC ACUTE KIDNEY INJURY TREATMENT MARKET SIZE, BY PHARMACOLOGICAL TREATMENT, 2018-2032 (USD MILLION)
  • TABLE 133. ASIA-PACIFIC ACUTE KIDNEY INJURY TREATMENT MARKET SIZE, BY SUPPORTIVE CARE, 2018-2032 (USD MILLION)
  • TABLE 134. ASIA-PACIFIC ACUTE KIDNEY INJURY TREATMENT MARKET SIZE, BY AKI TYPE, 2018-2032 (USD MILLION)
  • TABLE 135. ASIA-PACIFIC ACUTE KIDNEY INJURY TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 136. ASIA-PACIFIC ACUTE KIDNEY INJURY TREATMENT MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2032 (USD MILLION)
  • TABLE 137. GLOBAL ACUTE KIDNEY INJURY TREATMENT MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 138. ASEAN ACUTE KIDNEY INJURY TREATMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 139. ASEAN ACUTE KIDNEY INJURY TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 140. ASEAN ACUTE KIDNEY INJURY TREATMENT MARKET SIZE, BY DIALYSIS, 2018-2032 (USD MILLION)
  • TABLE 141. ASEAN ACUTE KIDNEY INJURY TREATMENT MARKET SIZE, BY PHARMACOLOGICAL TREATMENT, 2018-2032 (USD MILLION)
  • TABLE 142. ASEAN ACUTE KIDNEY INJURY TREATMENT MARKET SIZE, BY SUPPORTIVE CARE, 2018-2032 (USD MILLION)
  • TABLE 143. ASEAN ACUTE KIDNEY INJURY TREATMENT MARKET SIZE, BY AKI TYPE, 2018-2032 (USD MILLION)
  • TABLE 144. ASEAN ACUTE KIDNEY INJURY TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 145. ASEAN ACUTE KIDNEY INJURY TREATMENT MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2032 (USD MILLION)
  • TABLE 146. GCC ACUTE KIDNEY INJURY TREATMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 147. GCC ACUTE KIDNEY INJURY TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 148. GCC ACUTE KIDNEY INJURY TREATMENT MARKET SIZE, BY DIALYSIS, 2018-2032 (USD MILLION)
  • TABLE 149. GCC ACUTE KIDNEY INJURY TREATMENT MARKET SIZE, BY PHARMACOLOGICAL TREATMENT, 2018-2032 (USD MILLION)
  • TABLE 150. GCC ACUTE KIDNEY INJURY TREATMENT MARKET SIZE, BY SUPPORTIVE CARE, 2018-2032 (USD MILLION)
  • TABLE 151. GCC ACUTE KIDNEY INJURY TREATMENT MARKET SIZE, BY AKI TYPE, 2018-2032 (USD MILLION)
  • TABLE 152. GCC ACUTE KIDNEY INJURY TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 153. GCC ACUTE KIDNEY INJURY TREATMENT MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2032 (USD MILLION)
  • TABLE 154. EUROPEAN UNION ACUTE KIDNEY INJURY TREATMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 155. EUROPEAN UNION ACUTE KIDNEY INJURY TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 156. EUROPEAN UNION ACUTE KIDNEY INJURY TREATMENT MARKET SIZE, BY DIALYSIS, 2018-2032 (USD MILLION)
  • TABLE 157. EUROPEAN UNION ACUTE KIDNEY INJURY TREATMENT MARKET SIZE, BY PHARMACOLOGICAL TREATMENT, 2018-2032 (USD MILLION)
  • TABLE 158. EUROPEAN UNION ACUTE KIDNEY INJURY TREATMENT MARKET SIZE, BY SUPPORTIVE CARE, 2018-2032 (USD MILLION)
  • TABLE 159. EUROPEAN UNION ACUTE KIDNEY INJURY TREATMENT MARKET SIZE, BY AKI TYPE, 2018-2032 (USD MILLION)
  • TABLE 160. EUROPEAN UNION ACUTE KIDNEY INJURY TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 161. EUROPEAN UNION ACUTE KIDNEY INJURY TREATMENT MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2032 (USD MILLION)
  • TABLE 162. BRICS ACUTE KIDNEY INJURY TREATMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 163. BRICS ACUTE KIDNEY INJURY TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 164. BRICS ACUTE KIDNEY INJURY TREATMENT MARKET SIZE, BY DIALYSIS, 2018-2032 (USD MILLION)
  • TABLE 165. BRICS ACUTE KIDNEY INJURY TREATMENT MARKET SIZE, BY PHARMACOLOGICAL TREATMENT, 2018-2032 (USD MILLION)
  • TABLE 166. BRICS ACUTE KIDNEY INJURY TREATMENT MARKET SIZE, BY SUPPORTIVE CARE, 2018-2032 (USD MILLION)
  • TABLE 167. BRICS ACUTE KIDNEY INJURY TREATMENT MARKET SIZE, BY AKI TYPE, 2018-2032 (USD MILLION)
  • TABLE 168. BRICS ACUTE KIDNEY INJURY TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 169. BRICS ACUTE KIDNEY INJURY TREATMENT MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2032 (USD MILLION)
  • TABLE 170. G7 ACUTE KIDNEY INJURY TREATMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 171. G7 ACUTE KIDNEY INJURY TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 172. G7 ACUTE KIDNEY INJURY TREATMENT MARKET SIZE, BY DIALYSIS, 2018-2032 (USD MILLION)
  • TABLE 173. G7 ACUTE KIDNEY INJURY TREATMENT MARKET SIZE, BY PHARMACOLOGICAL TREATMENT, 2018-2032 (USD MILLION)
  • TABLE 174. G7 ACUTE KIDNEY INJURY TREATMENT MARKET SIZE, BY SUPPORTIVE CARE, 2018-2032 (USD MILLION)
  • TABLE 175. G7 ACUTE KIDNEY INJURY TREATMENT MARKET SIZE, BY AKI TYPE, 2018-2032 (USD MILLION)
  • TABLE 176. G7 ACUTE KIDNEY INJURY TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 177. G7 ACUTE KIDNEY INJURY TREATMENT MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2032 (USD MILLION)
  • TABLE 178. NATO ACUTE KIDNEY INJURY TREATMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 179. NATO ACUTE KIDNEY INJURY TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 180. NATO ACUTE KIDNEY INJURY TREATMENT MARKET SIZE, BY DIALYSIS, 2018-2032 (USD MILLION)
  • TABLE 181. NATO ACUTE KIDNEY INJURY TREATMENT MARKET SIZE, BY PHARMACOLOGICAL TREATMENT, 2018-2032 (USD MILLION)
  • TABLE 182. NATO ACUTE KIDNEY INJURY TREATMENT MARKET SIZE, BY SUPPORTIVE CARE, 2018-2032 (USD MILLION)
  • TABLE 183. NATO ACUTE KIDNEY INJURY TREATMENT MARKET SIZE, BY AKI TYPE, 2018-2032 (USD MILLION)
  • TABLE 184. NATO ACUTE KIDNEY INJURY TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 185. NATO ACUTE KIDNEY INJURY TREATMENT MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2032 (USD MILLION)
  • TABLE 186. GLOBAL ACUTE KIDNEY INJURY TREATMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 187. UNITED STATES ACUTE KIDNEY INJURY TREATMENT MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 188. UNITED STATES ACUTE KIDNEY INJURY TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 189. UNITED STATES ACUTE KIDNEY INJURY TREATMENT MARKET SIZE, BY DIALYSIS, 2018-2032 (USD MILLION)
  • TABLE 190. UNITED STATES ACUTE KIDNEY INJURY TREATMENT MARKET SIZE, BY PHARMACOLOGICAL TREATMENT, 2018-2032 (USD MILLION)
  • TABLE 191. UNITED STATES ACUTE KIDNEY INJURY TREATMENT MARKET SIZE, BY SUPPORTIVE CARE, 2018-2032 (USD MILLION)
  • TABLE 192. UNITED STATES ACUTE KIDNEY INJURY TREATMENT MARKET SIZE, BY AKI TYPE, 2018-2032 (USD MILLION)
  • TABLE 193. UNITED STATES ACUTE KIDNEY INJURY TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 194. UNITED STATES ACUTE KIDNEY INJURY TREATMENT MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2032 (USD MILLION)
  • TABLE 195. CHINA ACUTE KIDNEY INJURY TREATMENT MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 196. CHINA ACUTE KIDNEY INJURY TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 197. CHINA ACUTE KIDNEY INJURY TREATMENT MARKET SIZE, BY DIALYSIS, 2018-2032 (USD MILLION)
  • TABLE 198. CHINA ACUTE KIDNEY INJURY TREATMENT MARKET SIZE, BY PHARMACOLOGICAL TREATMENT, 2018-2032 (USD MILLION)
  • TABLE 199. CHINA ACUTE KIDNEY INJURY TREATMENT MARKET SIZE, BY SUPPORTIVE CARE, 2018-2032 (USD MILLION)
  • TABLE 200. CHINA ACUTE KIDNEY INJURY TREATMENT MARKET SIZE, BY AKI TYPE, 2018-2032 (USD MILLION)
  • TABLE 201. CHINA ACUTE KIDNEY INJURY TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 202. CHINA ACUTE KIDNEY INJURY TREATMENT MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2032 (USD MILLION)